drugset / Trial / NCT03565861
Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers
RandomizedSequentialTriple-blindTreatment
Summary
This study assesses the safety, tolerability and pharmacokinetics of NP10679 when delivered intravenously in escalating dose levels in comparison to placebo.
Timeline
- Start
- 2018-04-06
- Primary completion
- 2018-09-02
- Completion
- 2018-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NP10679 | Small molecule | 5 mg | Intravenous |
| Subject | NP10679 | Small molecule | 15 mg | Intravenous |
| Subject | NP10679 | Small molecule | 50 mg | Intravenous |
| Subject | NP10679 | Small molecule | 100 mg | Intravenous |
| Subject | NP10679 | Small molecule | 200 mg | Intravenous |
| Subject | NP10679 | Small molecule | 300 mg | Intravenous |
Indications
No indication recorded.